Trial Profile

A randomized, double-blind, placebo-controlled, phase 1, single ascending dose study of VIR-3434

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 23 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tobevibart (Primary)
Indications Hepatitis B
Focus Adverse reactions; Pharmacodynamics

Most Recent Events

22 May 2024 According to a Brii Biosciences media release, data from this study will be presented at the annual meeting of the European Association for the Study of the Liver, EASL Congress 2024, taking place in Milan, Italy from June 5-8.
25 Jun 2023 According to a Brii Biosciences media release, data from this trial were presented at the EASL (European Association for the Study of the Liver) Congress.
26 Dec 2022 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com